Variants in in a hospital-based cohort in Chile and national literature review.

Purpose: The aim was to assess the diagnostic yield of next generation sequencing (NGS) multi-gene panels for breast and ovarian cancer in a high-complexity cancer centre in Chile. Additionally, our goal was to broaden the genotypic spectrum of BRCA variants already identified in Chilean families.

Methods: Retrospective analysis was conducted on the genetic test results of 722 individuals from Fundación Arturo López Pérez's genetic counselling unit between 2016 and 2021. A comprehensive literature review encompassing articles analysing the frequency of germinal pathogenic variants in within the Chilean population was undertaken.

Results: 23.5% of the panels had positive results, with 60% due to pathogenic variants in the genes. Seven previously unreported variants in from Chilean studies were identified.One or more variants of uncertain significance were detected in 31% of the results, and 11.5% of the families in this cohort presented copy number variants (CNVs) in .8 studies analysed the frequency of pathogenic variants in in the Chilean population between 2006 and 2023, with a frequency between 7.1% and 17.1%.51 variants in 149 families have been reported in Chile and 38 variants in 132 families. Nine founder pathogenic variants identified by one study were present in 51.9% of the total Chilean families reported.

Conclusion: Our findings advocate for the integration of NGS multi-gene panel testing as a primary strategy within our population. This approach allows for the comprehensive assessment of single nucleotide variants and CNVs in , alongside other high and moderately penetrant genes associated with breast and ovarian cancer.